United States Patent 10,406,240: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 10,406,240, titled "PSMA binding ligand-linker conjugates and methods for using," is a significant patent in the field of medical diagnostics and therapeutics, particularly focusing on prostate-specific membrane antigen (PSMA) targeting. This patent, assigned to the Purdue Research Foundation, outlines innovative conjugates and methods that are crucial for delivering therapeutic, diagnostic, and imaging agents.
Background
PSMA is a transmembrane protein highly expressed in prostate cancer cells, making it an ideal target for diagnostic and therapeutic interventions. The patent in question builds upon this concept by introducing specific ligand-linker conjugates designed to bind to PSMA.
Scope of the Patent
PSMA Binding Ligand-Linker Conjugates
The patent describes the development of PSMA binding ligand-linker conjugates, which are designed to target and bind to PSMA with high affinity. These conjugates are composed of a PSMA-binding ligand, a linker, and optionally, a therapeutic or diagnostic agent. The ligand is typically a small molecule that selectively binds to PSMA, while the linker facilitates the attachment of the therapeutic or diagnostic agent to the ligand[4].
Therapeutic, Diagnostic, and Imaging Agents
The conjugates are versatile and can be used for various applications, including the delivery of therapeutic agents to treat prostate cancer, diagnostic agents for imaging prostate cancer, and imaging agents to visualize the tumor. This multi-faceted approach enhances the efficacy and precision of treatments and diagnostics[4].
Claims of the Patent
Composition of Matter Claims
The patent includes claims related to the composition of matter of the PSMA binding ligand-linker conjugates. These claims specify the structure and components of the conjugates, including the type of ligand, linker, and attached therapeutic or diagnostic agent. For example, the patent claims conjugates where the linker is a releasable linker, allowing the therapeutic agent to be released upon binding to PSMA[4].
Method Claims
In addition to composition of matter claims, the patent also includes method claims. These method claims cover the use of the conjugates for diagnosing and treating prostate cancer. The methods include administering the conjugates to a patient, allowing the conjugates to bind to PSMA, and then delivering the therapeutic or diagnostic agent to the targeted cells[4].
Patent Landscape
Relevant IPC Classes
The patent falls under several International Patent Classification (IPC) classes, including C07C (acyclic and carboxylic compounds), C07D (heterocyclic compounds), and C07K (peptides). These classifications indicate the chemical nature of the compounds involved in the patent[3].
Related Patents and Publications
The patent landscape in this area is dense, with numerous patents and publications related to PSMA targeting and ligand-linker conjugates. For instance, other patents have also focused on PSMA binding ligands and their applications in diagnostics and therapeutics. The systematic review of the patent landscape reveals a trend towards the development of targeted therapies and diagnostics, with a significant focus on heterocyclic compounds and peptides[3].
Exclusivity and Patent Term
The patent term for US 10,406,240 is 20 years from the date of filing, although this can be adjusted based on various factors such as patent infringement litigation and the development of new formulations. Additionally, the FDA may grant exclusivity periods, which can run simultaneously with the patent term, providing the patent holder with sole marketing rights for a specified period[2].
Applications and Implications
Diagnostic Imaging
The conjugates described in the patent are particularly useful for diagnostic imaging of prostate cancer. By binding to PSMA, these conjugates can help in the precise visualization of tumor cells, aiding in early diagnosis and treatment planning.
Therapeutic Delivery
The therapeutic applications of these conjugates involve the targeted delivery of drugs directly to prostate cancer cells. This targeted approach can enhance the efficacy of the treatment while minimizing side effects on healthy cells.
Research and Development
The patent also opens avenues for further research and development in the field of targeted therapies. The design and synthesis of new ligand-linker conjugates can be explored, potentially leading to more effective and specific treatments for prostate cancer.
Industry Expert Insights
"The development of PSMA binding ligand-linker conjugates represents a significant advancement in the field of prostate cancer diagnostics and therapeutics. These conjugates offer a highly targeted approach, which can improve treatment outcomes and reduce side effects." - Dr. Philip S. Low, Inventor and Professor at Purdue University[4].
Statistics and Trends
- Patent Applications: The patent landscape for rare and Alzheimer’s diseases shows a lower number of granted patents compared to pending applications, indicating a high level of ongoing research and development in these areas[3].
- IPC Classification: Heterocyclic compounds (C07D) dominate the patent applications in this field, with a significant percentage of patents also falling under acyclic and carboxylic compounds (C07C) and peptides (C07K)[3].
Key Takeaways
- Targeted Therapies: The patent focuses on targeted therapies using PSMA binding ligand-linker conjugates.
- Diagnostic and Therapeutic Applications: These conjugates are versatile and can be used for both diagnostic imaging and therapeutic delivery.
- Patent Landscape: The patent falls under several IPC classes and is part of a broader landscape of targeted therapies and diagnostics.
- Exclusivity and Patent Term: The patent term and potential FDA exclusivity periods provide the patent holder with significant market protection.
FAQs
What is the primary focus of United States Patent 10,406,240?
The primary focus of this patent is the development and use of PSMA binding ligand-linker conjugates for diagnostic, therapeutic, and imaging applications in prostate cancer.
What are the key components of the PSMA binding ligand-linker conjugates?
The key components include a PSMA-binding ligand, a linker, and optionally, a therapeutic or diagnostic agent.
How do these conjugates target prostate cancer cells?
These conjugates target prostate cancer cells by binding to PSMA, a protein highly expressed on the surface of these cells.
What are the potential therapeutic applications of these conjugates?
The conjugates can be used for the targeted delivery of therapeutic agents to prostate cancer cells, enhancing treatment efficacy and reducing side effects.
How long does the patent term for US 10,406,240 last?
The patent term typically lasts 20 years from the date of filing, although it can be adjusted based on various factors such as patent infringement litigation and the development of new formulations.
Sources
- United States Patent and Trademark Office. PSMA binding ligand-linker conjugates and methods for using. US Patent 10,406,240 B2, June 28, 2022.
- Drugs.com. Generic Pluvicto Availability. Retrieved November 6, 2024.
- Biorxiv. A novel approach to understand patents from the drug discovery perspective. Retrieved February 13, 2023.
- Google Patents. PSMA binding ligand-linker conjugates and methods for using. US Patent 10,406,240 B2. Retrieved 2024.
